QL1706 plus chemo before surgery for triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a combination of an immunotherapy drug (QL1706) plus standard chemotherapy given before surgery to shrink triple-negative breast cancer. The goal is to see if this approach helps remove the tumor more completely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have newly diagnosed triple-negative breast cancer (ER-negative, HER2-negative).
- Your cancer must be stage II or stage III and at least 2 cm in size, or you must have cancer in the lymph nodes.
- You cannot have received any chemotherapy, immunotherapy, or targeted therapy for this cancer before.
- You must be 18 or older and in generally good health (able to do most daily activities).
- You must not have serious heart disease, active infections like HIV or hepatitis, or other cancers in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy and immunotherapy given before surgery for early-stage triple-negative breast cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a new drug, QLC5513, given alone or with another drug called QL1706, for people with advanced or metastatic triple-negative breast cancer (TNBC) that has worsened after at least one previous treatment. The goal is to see if these drugs can shrink tumors or slow the cancer's growth.
This trial tests a combination of chemotherapy and two immunotherapy drugs given before surgery for women and men with triple-negative breast cancer. The goal is to see if this approach helps shrink or eliminate the tumor before surgery.
This trial tests a combination of an immunotherapy drug (QL1706) plus chemotherapy given before surgery to shrink early high-risk triple-negative breast cancer. The goal is to see if this treatment can improve the chance of a complete response (no cancer left at surgery).
This study tests whether adding a new immunotherapy drug called QL1706 to standard chemotherapy after surgery can help patients with aggressive triple-negative breast cancer that has spread to lymph nodes. The goal is to see if this combination prevents cancer from coming back.
This trial tests whether adding an experimental immunotherapy drug (QL1706) with or without bevacizumab to standard chemotherapy can help people with advanced triple-negative breast cancer that hasn't been treated yet. It aims to improve outcomes for patients who have already had earlier treatment but whose cancer has come back or spread.
Hear when a new Triple Negative Breast Cancer (TNBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.